Is Pfizer Stock Halal?
Pfizer Inc. · PFE · NYSE
Pfizer Inc. (PFE) is a methodology-divergence case: our AAOIFI computation on spot market cap (data as of 2026-03-29) breaches the interest-bearing debt / market cap limit (43.0% vs < 30%), yet professional Shariah index screens currently hold it — their methodologies use averaged market cap or different denominators, and borderline ratios move with the share price. We report it as conditional; follow the screening methodology you trust.
Financial data as of 2026-03-29 · Screening basis: AAOIFI · Last reviewed 2026-06-14
Our Analysis
Pfizer's underlying business, discovering and selling medicines and vaccines, is permissible, and it does not earn interest from lending. Its FY2025 revenue of $62,579 million is almost entirely product sales ($51,663 million) plus alliance and royalty income from its drug portfolio. On the activity screen, pharma is clean. The screening question for Pfizer is leverage.
After buying cancer-drug maker Seagen for roughly $43 billion in 2023, Pfizer took on a large amount of debt, and it is still working that down. At year-end 2025 it carried about $64.8 billion of total debt ($3,154 million short-term plus $61,641 million long-term) against total equity of $86,775 million. That elevated debt is precisely the kind of figure that Shariah financial-ratio screens scrutinize, and different methodologies measure it differently, some against total assets, others against market capitalization.
That difference appears to be why the two major US Shariah ETFs split on Pfizer: HLAL holds it (156,080 shares as of February 28, 2026), while SPUS does not include it as of June 11, 2026, even though Pfizer is in the S&P 500. SPUS's methodology adds a debt-to-market-cap cap of 30%, which a debt-heavy pharma can fail while still passing FTSE's formula. Neither fund publishes its reasoning, so this is the most likely explanation rather than a confirmed one. A Muslim investor should treat Pfizer as a permissible-business name whose compliance currently hinges on the debt ratio, and verify the live status in a screener, since deleveraging could change the answer.
Business Activity Screen
Pfizer Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines through its Biopharma segment. Per its FY2025 10-K, total revenues were $62,579 million (product revenues $51,663 million, alliance revenues $9,266 million, and royalty revenues $1,650 million), and net income attributable to Pfizer was $7,771 million.
Pharmaceutical development and manufacturing is a permissible business activity and is not on AAOIFI's prohibited-industry list; Pfizer has no interest-based lending business. The Shariah-relevant concern is leverage: following its 2023 acquisition of Seagen, Pfizer carries heavy interest-bearing debt. Per the FY2025 balance sheet, short-term borrowings (including current portion of long-term debt) were $3,154 million and long-term debt was $61,641 million (about $64.8 billion total), against total equity of $86,775 million; it held $1,142 million cash plus $12,454 million short-term investments. This debt load is the most plausible reason Pfizer is held by HLAL but not by SPUS, whose methodology additionally requires debt-to-market-cap below 30% (the funds do not publish per-stock reasons, so this is inferred, not confirmed).
Financial Ratio Screen
| Screen | Value | AAOIFI limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 43.0% | < 30% | Fail |
| Cash + interest-bearing securities / market cap | 8.7% | < 30% | Pass |
| Impermissible income / total revenueInterest income only — verify other impermissible revenue lines in the 10-K | 1.0% | < 5% | Pass |
Spot market cap at research date (consider trailing average for borderline names). Data as of 2026-03-29 · thresholds per AAOIFI Shariah standards.
This verdict uses the AAOIFI standard — the most widely used and, at a 30% debt limit, the most conservative mainstream Shariah standard. Interest-bearing debt and interest-bearing securities each stay under 30% of market cap, and impermissible income under 5% of revenue. Other standards (Dow Jones Islamic, S&P Shariah, MSCI Islamic, FTSE Yasaar) use ~33% limits or screen against total assets, so a borderline company can be rated differently by each. How we screen & why screeners disagree →
How Pfizer screens across Shariah standards
The standards disagree on this company. It passes some Shariah screens and fails others — which is exactly why you may see a different answer in different apps. Our headline verdict uses AAOIFI, the strictest and most widely cited mainstream standard.
| Standard | Debt | Cash & interest securities | Limit / basis | Result |
|---|---|---|---|---|
| AAOIFI (our standard) | 43.0% | 8.7% | < 30% of market cap | Fail |
| Dow Jones Islamic / S&P Shariah thresholdDow Jones and S&P apply this limit against a trailing 24–36-month average market cap; shown here on the same point-in-time market cap for comparison. | 43.0% | 8.7% | < 33% of market cap | Fail |
| MSCI Islamic / FTSE Yasaar basisTotal-assets denominator. MSCI/FTSE also apply entry/exit buffers and a receivables screen we do not reproduce. | 31.0% | 6.3% | < 33.33% of total assets | Pass |
HalalWallet computation reproducing each standard's threshold and denominator from public filings (balance sheet as of 2026-03-29) — not the providers' licensed index determinations, which can differ. Debt is interest-bearing borrowings (operating leases excluded). The impermissible-income screen (< 5% of revenue) is common to all of these standards and is shown in the ratio table above. Dow Jones and S&P apply their limit against a trailing 24–36-month average market cap; MSCI and FTSE add entry/exit buffers and a receivables screen. Full methodology →
Other stocks where Shariah screeners disagree
These companies pass under some mainstream standards and fail under others — the same pattern as this verdict. That is why two apps can show different answers.
AbbVieABBV
Passes market-cap screens · fails MSCI/FTSE (total assets)
AirbnbABNB
Passes market-cap screens · fails MSCI/FTSE (total assets)
Arista NetworksANET
Passes market-cap screens · fails MSCI/FTSE (total assets)
ArmARM
Passes market-cap screens · fails MSCI/FTSE (total assets)
BlockXYZ
Fails AAOIFI market-cap · passes MSCI/FTSE (total assets)
BroadcomAVGO
Passes market-cap screens · fails MSCI/FTSE (total assets)
Conditions
Our AAOIFI computation using spot market capitalization breaches a financial-ratio threshold, but professional Shariah index screens that currently hold Pfizer Inc. pass it — index methodologies typically use averaged market capitalization (or total assets) as the denominator, and borderline ratios move with the share price between filings. Treat as conditional: recompute against a trailing-average market cap and the latest filing before relying on either result, or follow the screener whose methodology you trust.
Scholars' & Screeners' Positions
Published positions, cited as stated. Screeners can reach different conclusions on the same company because of ratio timing and methodology differences — we report the disagreement rather than flatten it.
What to do instead
You don't have to choose between investing and your values — screened alternatives exist for nearly every position.
Related guides
Consider Consulting an Islamic Scholar
Major whether Pfizer Inc. is halal decisions often involve nuances that vary by scholarly opinion and personal circumstance. While HalalWallet provides educational comparisons and tools, we are not scholars or financial advisors. For personal guidance on Shariah compliance, consider speaking with a qualified Islamic scholar, your local imam, or a Shariah-certified financial advisor familiar with your situation.
Important: HalalWallet is an educational comparison platform. We do not provide financial, legal, or religious advice.
Product structures and Shariah-compliance oversight vary by provider. Before applying:
- Verify halal compliance directly with the provider.
- Review the contract structure (Murabaha, Ijara, Musharakah, etc.) and any disclosed Shariah board opinions.
- Consult a qualified Islamic finance advisor or scholar for guidance on your individual circumstances.
Frequently Asked Questions
Sources and review process
This page is reviewed against HalalWallet editorial standards and source documentation.
Reviewed by: HalalWallet Editorial Team
Last reviewed: 2026-06-01
- PFE latest quarterly filing (balance sheet 2026-03-29)
- AAOIFI Shariah Standards
- Pfizer FY2025 10-K consolidated statements of operations (SEC EDGAR XBRL)
- Pfizer FY2025 10-K consolidated balance sheets (debt detail) (SEC EDGAR XBRL)
- Pfizer FY2025 10-K (SEC EDGAR primary document)
- SPUS holdings (SP Funds)
- HLAL Schedule of Investments 2026-02-28 (SEC EDGAR)
- HalalWallet Methodology
- Editorial Policy
How to cite this page
Preferred format:
For time-sensitive claims (rates, fees, state availability), please verify directly with the provider's official documentation and note the retrieval date.
Editorial Team, HalalWallet
Independent halal finance research
Reviewed quarterly and updated for major content changes.